Zurich, Switzerland – October 1st, 2022 – Navignostics is delighted to welcome Eleni Tselempi, who is joining the team as a product developer. Eleni got her Master of Science in Cancer Biology in Bernd Bodenmiller’s lab, five years ago and has been working in cancer immunotherapy research with Roche Glycart AG ever since. She will take a lead role in driving the product development at Navignostics.
With her experimental and analytical skills in the field of cancer research and the applications of innovative technologies on drug discovery and patient stratification, Eleni brings the perfect expertise to design and further develop diagnostic products according to quality standards. In addition, Eleni is familiar with tissue engineering and computational biology and has extensive experience with high dimensional single cell analysis.
Eleni is excited to being part of Navignostics’ team: ”Leveraging innovative approa-ches for developing high quality diagnostic tools is a key component of a successful treatment!”
Navignostics is a spin-off company from the University of Zurich, founded in April 2022, which is leveraging spatial single-cell proteomics to perform advanced analyses of tumor samples. As a start–up active in the personalized medicine field, Navignostics strives to provide innovative solutions to identify the best possible treatment for each cancer patient. In addition, Navignostics provides advanced services to pharmaceutical companies to accelerate cancer drug development and to contribute to companion diagnostic development.